Robot Lecture Hall, February 10, recently, the exoskeleton leader Hangzhou Chengtian Technology Development Co., Ltd. announced the completion of a hundred million yuan A+ round of financing, this round of financing led by Dachen Caizhi, Anxin Securities, Poly Capital with investment, old shareholder Lanchi Venture Capital continued to follow, Potential Capital as the exclusive financial adviser for this financing.
It is reported that ChengTian Technology is the first innovative medical robot company in the industry to be approved to apply the NMPA registration certificate of lower limb exoskeleton robot with central neuropathy (covering patients with paraplegia, hemiplegia, cerebral palsy, etc.). In addition, in 2021, Cheng Tian Technology has successively obtained the marketing license of 8 models in 3 categories in this field, and was selected by KPMG's "China Social Rehabilitation Medical 50 Enterprise Report" and won the "Leading Rehabilitation Technology Enterprise Award". In 2021, ChengTian Technology won more than 10 awards in the field of medical rehabilitation, including 5 international design awards including Red Dot Award, IF Design Award, Golden Dot Award, etc., and has more than 300 independent intellectual property rights.
Cheng Tian Technology's financing will be used to enhance the core operational capabilities of enterprise grouping and continue to maintain the leading position of commercialization, expand the global business scope, and promote in-depth cooperation with top international research institutions and clinical institutions. At the same time, ChengTian Technology will also increase investment in products, talents, technologies and supply chains, enrich the C-end product matrix, promote the consumer-grade Internet exoskeleton technology service platform based on AI technology, and consolidate the industry's leading position.
It is understood that the next stage of ChengTian Technology's development plan will strengthen industry expansion cooperation in providing intelligent products and solutions for medical and health care institutions and individual users, maintain a leading position in business; build an open C-end consumer operation platform, expand the product matrix, and create C-end consumer-grade exoskeleton services; break through core technology upgrades, and set up strong industry barriers in the integration of exoskeleton and brain-computer interface technology. For more information or cooperation, welcome to pay attention to the official WeChat of Robot Lecture Hall (Name: Robot Lecture Hall, ID: RoboSpeak)